Overview Dividends

(ADCT) ADC Therapeutics - Ratings and Ratios

Exchange: NYSE • Country: Switzerland • Currency: USD • Type: Common Stock • ISIN: CH0499880968

Antibody Conjugates, Zynlonta, CD19, Lymphoma, Pipeline

Communications Equipment
Market Cap in USD: 436m

IPO / Inception: 1979-03-16
Return 12m vs S&P 500: 55.2%

EPS (Earnings per Share)

EPS CAGR: 6.33%
EPS Trend: 55.5%

Last SUE: 1.29
Qual. Beats: 1

Revenue

Rev. CAGR: -0.93%
Rev. Trend: -42.8%

Last SUE: -0.16
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	87.8%
Value at Risk 5%th	129%
Relative Tail Risk	-10.68%

Reward TTM
Sharpe Ratio	1.01
Alpha	49.84
CAGR/Max DD	-0.07

Character TTM
Hurst Exponent	0.542
Beta	1.479
Beta Downside	1.008

Drawdowns 3y
Max DD	91.41%
Mean DD	49.93%
Median DD	49.72%

Description: ADCT ADC Therapeutics January 01, 2026

ADC Therapeutics SA (NYSE:ADCT) is a Swiss biotech that has built an antibody-drug conjugate (ADC) platform aimed at delivering cytotoxic payloads directly to cancer cells, focusing on both hematologic malignancies and solid tumors.

Its lead product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed ADC that has earned accelerated U.S. FDA approval, conditional EU approval, and conditional Chinese NMPA approval for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after ≥ 2 prior lines of therapy.

ADCT is pursuing broader indications for ZYNLONTA, including earlier-line DLBCL, follicular lymphoma (FL) and marginal-zone lymphoma (MZL), via the confirmatory LOTIS-5 Phase 3 trial, the LOTIS-7 Phase 1b combination study, and multiple investigator-initiated trials (IITs). The pipeline also contains a CD22-targeted ADC (ADCT-602) in a Phase 1/2 IIT for refractory B-cell ALL and pre-clinical ADC candidates against Claudin-6, NaPi2b, PSMA, and ASCT2.

Key market metrics: the global ADC market is projected to grow at a CAGR of ~ 12 % through 2030, driven by higher oncology spending (U.S. oncology drug sales > $120 bn in 2023) and regulatory incentives for targeted therapies. ADCT’s cash runway exceeded $150 million at year-end 2023, and ZYNLONTA generated ~$45 million in Q4 2023 sales, reflecting early commercial traction in a niche but expanding CD19-ADC space.

For a deeper, data-driven assessment of ADCT’s valuation assumptions and scenario analysis, you may find the ValueRay platform worth a quick look.

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income (-166.9m TTM) > 0 and > 6% of Revenue (6% = 4.51m TTM)

FCFTA -0.46 (>2.0%) and ΔFCFTA -7.05pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 299.3% (prev 375.2%; Δ -75.89pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.46 (>3.0%) and CFO -131.9m > Net Income -166.9m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 4.63 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (136.4m) change vs 12m ago 30.17% (target <= -2.0% for YES)

Gross Margin 92.73% (prev -83.44%; Δ 176.2pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 23.55% (prev 20.26%; Δ 3.29pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -2.30 (EBITDA TTM -113.5m / Interest Expense TTM 50.5m) >= 6 (WARN >= 3)

Altman Z'' -18.90

(A) 0.78 = (Total Current Assets 287.1m - Total Current Liabilities 62.0m) / Total Assets 289.8m

(B) -5.62 = Retained Earnings (Balance) -1.63b / Total Assets 289.8m

warn (B) unusual magnitude: -5.62 — check mapping/units

(D) -3.07 = Book Value of Equity -1.62b / Total Liabilities 527.9m

Total Rating: -18.90 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 55.28

1. Piotroski 1.50pt

2. FCF Yield -41.52%

3. FCF Margin data missing

4. Debt/Equity -0.49

5. Debt/Ebitda 1.03

6. ROIC - WACC (= 98.81)%

7. RoE 76.04%

8. Rev. Trend -42.78%

9. EPS Trend 55.49%

What is the price of ADCT shares?

As of January 07, 2026, the stock is trading at USD 3.54 with a total of 818,759 shares traded.
Over the past week, the price has changed by +1.14%, over one month by +9.94%, over three months by -20.09% and over the past year by +82.47%.

Is ADCT a buy, sell or hold?

ADC Therapeutics has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy ADCT.

Strong Buy: 4
Buy: 2
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ADCT price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	8	126%
Analysts Target Price	8	126%
ValueRay Target Price	3.9	10.2%

ADCT Fundamental Data Overview January 04, 2026

Market Cap USD = 436.0m (436.0m USD * 1.0 USD.USD)
P/S = 5.7978
P/B = 2.5787
Beta = 1.894
Revenue TTM = 75.2m USD
EBIT TTM = -116.1m USD
EBITDA TTM = -113.5m USD
Long Term Debt = 115.2m USD (from longTermDebt, last quarter)
Short Term Debt = 933.0k USD (from shortTermDebt, last quarter)
Debt = 117.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -117.5m USD (from netDebt column, last quarter)
Enterprise Value = 318.6m USD (436.0m + Debt 117.3m - CCE 234.7m)
Interest Coverage Ratio = -2.30 (Ebit TTM -116.1m / Interest Expense TTM 50.5m)
FCF Yield = -41.52% (FCF TTM -132.3m / Enterprise Value 318.6m)
FCF Margin = -175.9% (FCF TTM -132.3m / Revenue TTM 75.2m)
Net Margin = -222.0% (Net Income TTM -166.9m / Revenue TTM 75.2m)
Gross Margin = 92.73% ((Revenue TTM 75.2m - Cost of Revenue TTM 5.47m) / Revenue TTM)
Gross Margin QoQ = 92.68% (prev 95.56%)
Tobins Q-Ratio = 1.10 (Enterprise Value 318.6m / Total Assets 289.8m)
Interest Expense / Debt = 11.42% (Interest Expense 13.4m / Debt 117.3m)
Taxrate = -0.0% (0.0 / -41.0m)
NOPAT = -116.1m (EBIT -116.1m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 4.63 (Total Current Assets 287.1m / Total Current Liabilities 62.0m)
Debt / Equity = -0.49 (negative equity) (Debt 117.3m / totalStockholderEquity, last quarter -238.2m)
Debt / EBITDA = 1.03 (negative EBITDA) (Net Debt -117.5m / EBITDA -113.5m)
Debt / FCF = 0.89 (negative FCF - burning cash) (Net Debt -117.5m / FCF TTM -132.3m)
Total Stockholder Equity = -219.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -57.61% (Net Income -166.9m / Total Assets 289.8m)
RoE = 76.04% (negative equity) (Net Income TTM -166.9m / Total Stockholder Equity -219.6m)
RoCE = 111.2% (negative capital employed) (EBIT -116.1m / Capital Employed (Equity -219.6m + L.T.Debt 115.2m))
RoIC = 110.3% (negative operating profit) (NOPAT -116.1m / Invested Capital -105.3m)
WACC = 11.46% (E(436.0m)/V(553.3m) * Re(11.47%) + D(117.3m)/V(553.3m) * Rd(11.42%) * (1-Tc(-0.0)))
Discount Rate = 11.47% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 11.52%
Fair Price DCF = unknown (Cash Flow -132.3m)
EPS Correlation: 55.49 | EPS CAGR: 6.33% | SUE: 1.29 | # QB: 1
Revenue Correlation: -42.78 | Revenue CAGR: -0.93% | SUE: -0.16 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.28 | Chg30d=+0.005 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=-1.11 | Chg30d=+0.200 | Revisions Net=+3 | Growth EPS=+21.5% | Growth Revenue=+3.9%

Additional Sources for ADCT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle